Analytical Data
-
Gene name
CCL25
- Application
-
Alternative Names
CCL25；SCYA25；TECK；C-C motif chemokine 25
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15444
-
Expression Region
24-150aa
-
AA Sequence
M+QGVFEDCCL AYHYPIGWAV LRRAWTYRIQ EVSGSCNLPA AIFYLPKRHR KVCGNPKSRE VQRAMKLLDA RNKVFAKLHH NTQTFQAGPH AVKKLSSGNS KLSSSKFSNP ISSSKRNVSL LISANSGL
-
Molecular Weight
14.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL25, also known as thymus-expressed chemokine (TECK), is a human chemokine that plays a crucial role in the migration and localization of T lymphocytes, particularly in the mucosal immune response. It is predominantly expressed in the thymus and intestinal tissues, where it facilitates the homing of naive T cells to gut-associated lymphoid tissues (GALT). The study of CCL25 has garnered significant interest due to its potential applications in understanding autoimmune diseases, inflammatory bowel disease, and various cancers, as it is involved in the recruitment of immune cells to sites of inflammation. Recent advancements in recombinant protein technology have enabled the production of CCL25 in large quantities, allowing researchers to investigate its structural and functional properties. This recombinant protein serves as a valuable tool in elucidating the signaling pathways and biological mechanisms underlying T cell trafficking. Moreover, CCL25's role as a therapeutic target is being explored, with the potential to develop novel treatments that modulate immune responses in various pathological conditions. Understanding CCL25's interactions with its receptors and its downstream signaling pathways could pave the way for innovative therapeutic approaches in immunology and oncology. As such, research on CCL25 recombinant proteins continues to be a significant area of interest, offering insights into the complexities of immune system regulation and potential intervention strategies for immune-mediated diseases.
